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Abstract
Background: Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive
disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing
oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk
of mortality due to associated comorbidities.
Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising
candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical
assays with CACs have shown promising results. A better understanding of how these cells participate in vascular
regeneration would significantly help to potentiate their role in revascularization.
Herein, we analyzed the initial molecular mechanisms triggered by human CACs after being administered to a
murine model of CLI, in order to understand how these cells promote angiogenesis within the ischemic tissues.
Methods: Balb-c nude mice (n:24) were distributed in four different groups: healthy controls (C, n:4), shams
(SH, n:4), and ischemic mice (after femoral ligation) that received either 50 μl physiological serum (SC, n:8) or 5 × 105
human CACs (SE, n:8). Ischemic mice were sacrificed on days 2 and 4 (n:4/group/day), and immunohistochemistry
assays and qPCR amplification of Alu-human-specific sequences were carried out for cell detection and vascular
density measurements. Additionally, a label-free MS-based quantitative approach was performed to identify protein
changes related.
Results: Administration of CACs induced in the ischemic tissues an increase in the number of blood vessels as well
as the diameter size compared to ischemic, non-treated mice, although the number of CACs decreased within time.
The initial protein changes taking place in response to ischemia and more importantly, right after administration of
CACs to CLI mice, are shown.
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Conclusions: Our results indicate that CACs migrate to the injured area; moreover, they trigger protein changes
correlated with cell migration, cell death, angiogenesis, and arteriogenesis in the host. These changes indicate that
CACs promote from the beginning an increase in the number of vessels as well as the development of an
appropriate vascular network.
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Introduction
Critical limb ischemia (CLI) constitutes the most
aggressive form of peripheral arterial obstructive
disease (PAOD), a cardiovascular disease (CVD)
mainly caused by atherosclerosis, resulting in block-
ade of arteries supplying blood to the lower extre-
mities [1]. CLI presents as rest pain, ischemic
ulceration, or foot gangrene. Patients with CLI have
a high risk of limb loss and fatal or non-fatal vascu-
lar events, such as myocardial infarction (MI) and
stroke [1]. This disease affects more than 202 mil-
lion people around the world and up to 10–15% of
the aged adult population [2]. CLI reduces signifi-
cantly the quality of life of patients, which usually
undergo amputation of the fingers, toes, or extrem-
ities, with an annual rate of amputation of 30% and
25% of mortality related [3–5]. In addition, meta-
bolic alterations such as diabetes mellitus signifi-
cantly increase the risk of PAOD, accelerating its
course and making these patients more susceptible
to ischemic events and impaired functional status
compared to patients without diabetes [6].
Unfortunately, no drugs have been approved for
the treatment of PAOD or CLI, and the available
symptomatic treatments are ineffective [7]. Conven-
tional surgical revascularization is not possible in
50–90% of patients due to high comorbidity [8, 9].
Moreover, approximately 30–50% of patients will re-
quire repeated interventions as treatments are often
ineffective and fail within 1 year [10]. Thus, angio-
genic therapy, which involves the use of an exo-
genous stimulus to promote blood vessel growth, is
a highly promising approach for the treatment of
ischemic diseases [11]. In this sense, endothelial
progenitor cells (EPCs) have arisen as promising
candidates for therapeutic applications pursuing
tissue revascularization such as in CLI due to their
assigned vascular regenerative properties [12]. Since
their discovery in 1997 [13], many researchers have
explored the potential of using EPCs in tissue engin-
eering as an angiogenic source for vascular repairing
[14, 15], with many publications also focused on the
controversy regarding isolation techniques as well as
the definition of EPC phenotypes, presenting still a
variety of results in terms of surface-based EPC
markers [14, 16, 17]. In this regard, a consensus has
been reached at least in the need to discriminate be-
tween two different populations of the so-called
EPCs, depending on the differentiation status or
their capability to form colonies [17–20]: early EPCs
(eEPCs), also defined as circulating angiogenic cells
(CACs) or myeloid angiogenic cells (MACs), and late
outgrowth EPCs or endothelial colony-forming cells
(ECFCs). Both populations seem to play a significant
role in the revascularization process, the first ones
more likely in a paracrine fashion (not so much
deriving into an endothelial phenotype) while ECFCs
participate by replacing damaged endothelial cells
(ECs) [15, 17].
The discovery of EPCs has promoted the development
of cell-based therapies applied in ischemic cardiovascular
diseases including PAOD [21]. Bone marrow (BM) or
peripheral blood (PB) mononuclear cells (MNCs), in-
cluding EPCs as well as EPC-enriched fractions, have
been preclinically applied with promising results, en-
couraging the design of clinical trials [21–23]. Among
them, the use of EPCs (CD34 + CD133+) from G-CSF-
mobilized blood administrated intramuscularly in a
small group of patients with no-option CLI resulted in a
safe and feasible therapy for these patients, with pain re-
duction and increase of vascular perfusion [24, 25].
Overall, clinical trials of cell therapy for PAOD/CLI have
shown promising results, but they are still in early-phase
stages [21]. On the other hand, the high variability seen
between the clinical results [21, 23], as well as the fact
that EPC quantity and function seem to be impaired
under pathological circumstances [26] makes compul-
sory the need to better understand how these cells work
and participate in restoration of ischemic tissues in order
to implement their clinical use. In this regard, in vitro
and in vivo assays have shown that EPCs (both CACs
and ECFCs) are susceptible to inflammatory and pro-
atherogenic factors such as ox-LDL, GM-CSF, SDF-1, or
IL-8, alone or combined, promoting an increased neo-
vascularization of ischemic tissues with pre-stimulated
cells [12, 27]. Very recently, we have shown that the in-
cubation ex vivo of CACs with atherosclerotic factors
promoted an increased mobilization of these cells, as
well as an increased expression of vasculogenic-related
markers [12].
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In the current approach, we focused on the analysis
of CACs, in order to confirm their involvement in tis-
sue revascularization. Thus, an in vivo assay was per-
formed, with CACs being administered to CLI mice,
in order to identify the molecular changes detected in
the ischemic tissues right after the injury and, more-
over, in response to the treatment with CACs. By
using a quantitative proteomic assay, we show protein
changes promoted in the first days after cell adminis-
tration within the damaged tissues. Furthermore, the
proteins identified correlated with cell migration,
angiogenesis, and other processes related to ischemia
and vascular repair.
Methods
Cell isolation and culture
Circulating pro-angiogenic cells, hereafter referred
to as CACs, were isolated from the peripheral blood
of healthy donors, as previously described [12].
Briefly, fresh peripheral blood mononuclear cells
(PBMCs) were isolated and plated in fibronectin-
coated plates (10 μg/ml) and incubated in 2% FBS/
EBM-2 media containing SingleQuots growth factors
(Lonza). Non-adherent cells were discarded after 4
days, and attached cells were allowed to grow until
day 7 in fresh media, when CACs were used for
experiments.
Cell characterization
Cell identity was confirmed by flow cytometry analysis,
using specific antibodies against CD31, CD34, CD45,
CD90, CD73, CD105, CD309, CD133-PE, CD146, and
CD14 molecular markers, as described [17]. An isotype
IgG1 antibody was used for negative control (Becton-
Dickinson 345816). The full list of antibodies is shown
in supplementary Table S5.
Additionally, uptake of acetylated LDL (ac-LDL), a
function associated with endothelial cells, was
assessed as previously described [12]. On day 7, cul-
tured cells were incubated with 4 μg/mL DiI-Ac-LDL
for 4 h. Cells were then fixed with 4% paraformalde-
hyde (PFA) and incubated with 10 μg/mL FITC-
labeled Ulex europaeus agglutinin-I (UEA-1, lectin)
for 1 h. DiI-Ac-LDL/lectin double-positive cells were
identified as CACs.
Animals
Balb-C Nude (CAnN.Cg-Foxn1nu/Crl) mice (n:28),
age 9 weeks, were obtained from Charles River La-
boratories. Mice were allocated in special rooms in
specific cages, with technical staff, constantly super-
vising filters and air recirculation. Animals were fed
sterile standard chow diet ad libitum and had free ac-
cess to sterile water. Additionally, animals were
constantly monitored to carry out euthanasia in case
of excessive suffering or the presence of symptoms
(such as infection) which would likely affect the ex-
periment results. No animal was sacrificed prema-
turely during the experiment although one mouse
from group SE4 died and was not included in the
final analysis.
CLI model and cell administration
Mice were randomly allocated between the groups.
Mice were anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg) administered intraperitoneally
before surgery. Ischemia was induced in the left limb
by double ligation of the femoral artery, occluding the
distal and proximal ends of the femoral artery with
double knots (non-absorbable 6/0) of suture, as
described [28]. Additionally, mice received ketoprofen
(2 mg/kg) intraperitoneally during 3 days after
surgery.
Mice received 3–4 intramuscular injections in dif-
ferent sites of the left limb muscles, low back, low
frontal, and middle muscles (supplementary figure
S1), administrating either 5 × 105 CACs in 50 μl
physiological serum (treated group; SE, n:8) or 50 μl
physiological serum without cells (ischemic group; SC,
n:8), 24 h after surgery. Additionally, a healthy control
(C, n:4) and a sham surgical control group (SH, n:4),
undergoing femoral artery isolation, without ligation,
were also used. Shams were used for proteomic assays
while healthy controls were used in the analysis of
vascular density changes.
Blood flow was measured at baseline for both paws,
right after surgery and every day of the study, using a
Laser Doppler system (Periflux System 5000; Perimed).
Perfusion was expressed as a ratio of the left (ischemic)
to right (non-ischemic) limb.
Cell pre-labeling assay
In addition to the groups described in Section 2.4,
another set of Balb-C Nude mice (n:8) were employed
to confirm the presence of human CACs within the
injured area, by using a pre-labeling approach. Thus,
CACs (2 × 106) were pre-labeled with Lectin-Ulex
europaeus Agglutinin I (UEA1) (1:300), 1 h at 37 °C,
and 5% CO2 and washed several times with PBS 1X
before being administered (5 × 105 cells/mouse) to
mice that underwent femoral ligation 24 h earlier, as
described above.
Tissue extraction
Mice from groups SE and SC were sacrificed (n:4 per
group) on days 2 and 4 after surgery (SE2, SE4, SC2,
and SC4), while the SH (sham) and C (healthy con-
trols) were sacrificed on day 1 (Fig. 1a). Mice treated
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Fig. 1 CLI progression, blood flow changes, and vasculogenesis in ischemic vs CAC-treated mice. a Schematic representation of experimental
mice distribution. b Blow flow evolution per group (C, SH, SC, and SE) within time. Averaged ratios of the left (injured) vs right (non-injured) limbs
are shown. c Representative images of ischemic symptoms (inflammation, necrotic fingers) in SE and SC mice. d IHC images to measure vascular
density and diameter size, using anti-mouse smooth muscle α-actin (red) and DAPI (blue). e The number of vessels (vessels/mm2) and f diameter
size (μm) were calculated in SE and SC groups vs C (healthy controls). g Vessel classification based on abundance percentage of different ranges
of internal lumen areas (μm2). Groups analyzed: C: healthy control (n:4); SH: sham, surgery controls (n:4); SC: ischemic mice, no cell treatment (n:4);
SE: ischemic mice, CAC treatment (day 2, n:4 and day 4, n:3). Data were presented as mean ± SEM. Significant differences were seen by two-way
ANOVA (b) and one-way ANOVA (e, f) and Tukey post hoc in all cases. *p value < 0.05, **p value < 0.01, ***p value < 0.001
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with pre-labeled CACs were also sacrificed on days 2
(n:4) and 4 (n:4). All mice were sacrificed in a CO2
chamber. For all of them, the muscles of the hind
limb were harvested (supplementary figure S1): the
low frontal muscles (tibialis) of the left limb were
embedded in 10% formaldehyde for 15 days and 30%
sucrose during 24 h, before OCT congelation for
appropriate preservation prior immunohistochemistry
(IHC). The low back (gastrocnemius and soleus) and
middle muscles (bicep femoris, adductor, and semi-
membranous) of the left limb were snap-frozen in
liquid N2 and stored at − 80 °C for further Alu-based
quantification and proteomic analysis.
Immunohistochemistry analysis
IHC was performed with tissue sections from SE and
SC groups, in order to detect human (h) cells and
vessel formation after cell administration, as well as
neutrophil mobilization toward the ischemic tissues.
Thus, OCT embedded sections of the low frontal
muscles (8 μm) coated in poly-lysine slides were pre-
treated with 1% SDS for 5 min for antigen retrieval
and with 1% triton, 20 min, for permeabilization be-
fore blocking with 5% goat serum and 0.1% triton, 1
h. Then, tissue sections were incubated with primary
antibodies overnight, labeling with UEA1 (1:300),
anti-α-actin smooth muscle (1:500), anti-hCD31 (1:
500), and anti-mouse Ly-6G (1:500) antibodies. After
that, tissue slides were incubated with 0.3% Sudan
Black B-70% ethanol for 20 min, to eliminate tissue
auto-fluorescence. Further incubation with specific
secondary antibodies for 1 h at room temperature
(RT), in the dark, was carried out (see Table S5 for
detailed information regarding antibodies). Finally, nu-
clear staining was done by incubation with DAPI
(0.2 μg/ml).
In total, 5 tissue sections (8 μm), separated by
16 μm each, were used per mouse (from the low
frontal muscles), analyzing the entire tissue areas of
each section by fluorescence microscopy, for cellular
and blood vessel detection. Images were acquired at
× 20, using a MMI CellCut Plus (Olympus) and visu-
alized with the Zen 2 (Zeiss) software. Results were
expressed as the number of cells per square milli-
meter, the number of blood vessels per square milli-
meter, or blood vessel diameter (μm) and area (μm2).
Additionally, the number of positive blood vessels
with UEA1+ cells per total number of vessels was
also quantified, as described [29]. Results were
expressed as the mean ± SEM.
Alu-based quantification
Human DNA (hDNA) was quantified by using the Alu-
detection approach, as described [30]. Genomic DNA
from the middle muscles was extracted with Quick-
DNA™ Midiprep Plus Kit (ZymoResearch D4075) after
Proteinase K (ZymoResearch D3001-2-B) treatment.
Alu sequences were amplified in 100 ng of genomic
DNA by qPCR using TaqMan Universal Master Mix II
(ThermoFisher 4440043), and 0.2 μM of primers and
0.25 μM of hydrolysis probes designed by [30]: forward
primer 5′-GGTGAAACCCCGTCTCTACT-3′, reverse
primer 5′-GGTTCAAGCGATTCTCCTGC-3′ and label
probe 5′-(6-FAM)-CGCCCGGCTAATTTTTGTAT-
(BHQ-1)-3′ (synthesized by Metabion). qPCR was per-
formed using a CFX Connect Real-Time System (Biorad)
with the following protocol: 1 cycle of 95 °C/10 min and
50 cycles of 95 °C/15s, 56 °C/30s and 72 °C/30s. CT
values were analyzed with Bio-Rad CFX manager soft-
ware (BioRad).
A standard curve was calculated with known
amounts of hDNA (from 5 ng to 1 pg) mixed with
murine DNA to determine the quantity of hDNA in
experimental tissue samples, as described [30]. qPCR
was performed in triplicates and Cq mean values were
plotted to obtain the linear equation as well as the R2
values (supplementary figure S3).
The amount of hDNA detected in 100 ng of total
genomic DNA extracted from the muscles was mea-
sured by qPCR, and further extrapolation of the total
hDNA extracted was then calculated per milligram of
the muscle. In the same way, the amount of DNA
(ng) per cell was calculated, considering the relation
of 5 pg of DNA per human cell [31]. Results were
expressed as the mean ± SEM of hDNA per milligram
of the muscle and human cells per milligram of the
muscle detected.
Proteomic analysis
The muscles from the left limbs were resuspended
in lysis buffer (1% NP40, 50 mM HEPES pH 7, 150
mM NaCl, and 1 mM EDTA, supplemented with
protease inhibitors) and homogenized by a mechan-
ical procedure for protein extraction. Proteins
(100 μg) were precipitated with 100% acetone over-
night at − 20 °C. Pellets were resuspended in 6M, re-
duced (10 mM DTT), and alkylated (50 mM IAA)
before in-solution digestion with Lys-C (Promega)
(enzyme/substrate ratio 1:65) for 4 h at RT. Samples
were diluted four times with 50 mM ammonium
bicarbonate and trypsin digested (ThermoFisher) (en-
zyme/substrate ratio 1:50) at 37 °C overnight. Finally,
the digestion was quenched with 0.1%TFA before
peptide purification with C18 columns. Peptide mix-
tures were analyzed by nano-LC-MS/MS on an Orbi-
trap Q-Exactive HF-X (ThermoFisher) coupled to an
EASY-LC 1000 system (Thermo Fischer Scientific).
Peptides were loaded onto a 150 ID EASY-SPRAY
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column in A-buffer (0.1% formic acid). After wash-
ing, the peptides were eluted at a flow rate of 1.2 μl/
min with an increasing gradient of B-buffer (95%
acetonitrile in 0.1% formic acid). The gradient was
stating at 2%B, going to 28%B in 80 min and to
40%B in 90 min. The Q-Exactive HFX was operated
in data-dependent acquisition mode using the fol-
lowing settings: full-scan automatic gain control
(AGC) target 3e6 at 120000 FWHM resolution, scan
range 350–1400 m/z, orbitrap full-scan maximum in-
jection time 100 ms, MS2 scan AGC target 1e5 at
15000 FWHM resolution, maximum injection 50 ms,
normalized collision energy 30, dynamic exclusion
time 20 s, isolation window 1.2 m/z, and 20 MS2
scans per MS full scan.
In order to identify proteins differently expressed
between ischemic vs non-ischemic conditions and,
moreover, in response to CAC treatment, all four
groups (SE, SC, SH, and C) were compared, including
time-related changes as well, n:4 per group (C, SH,
SC2, SC4, SE2) and SE4 (n:3, one died before). Tech-
nical duplicates for each biological sample, SE and SC
(n:4 per day) and SH and C (n:4), were run by LC-
MS/MS.
Protein identification was performed using Proteo-
meDiscoverer 2.2 software (Thermo Fisher Scientific),
searching against the Uniprot mouse database (tax-
onomy, mouse; 54,424 protein entries) using Mascot
(version 2.3.0.2, Matrix Science Ltd). The following
criteria were used: fixed modification: carbamidometh-
ylation (C); dynamic modifications: oxidation (M),
protein N-terminal acetylation, precursor mass toler-
ance 15 ppm; fragment mass tolerance 0.05 Da; en-
zyme: trypsin; and 2 missed cleavages were allowed.
Data filtering was performed using a percolator,
resulting in 1% false discovery rate (FDR). Additional
filters were search engine rank 1 peptides and Mascot
ion score > 20.
Additionally, an ion intensity-based label-free
quantification was performed, comparing all groups
between themselves and between times. Comparisons
vs the sham group (SH) were made to discard
changes due to surgery handling, while C was used
as healthy, basal levels. Differentially expressed pro-
teins were defined as follows: p value (t test) < 0.05
and fold-change rates > 1.5 for upregulated or < 0.6
for downregulated, for proteins identified in at least
2 replicates. Data processing and graphs were done
with Perseus (hierarchical cluster), Proteome Discov-
erer (plots and PCA analysis), and Venny 2.1 (Venn’s
diagram). Clustering was done with the following
parameters: Euclidian distances for cluster conditions
(upper tree) and Euclidean (normal) distance
between proteins. The Ingenuity Pathway Analysis
(IPA; Qiagen) platform was used for functional clas-
sification analysis of identified proteins.
Validation of protein changes detected
In order to validate the MS data, the levels of Apo-E
protein were measured by western blot (WB). Pro-
teins from tissue lysates (15 μg) were resuspended in
Laemmli sample buffer (50 mM Tris pH 6.8, 10% v/v
glycerol, 2% w/v SDS, 0.1% w/v bromophenol blue)
and separated on 4–15% polyacrylamide stain-free
gels, transferred to a PVDF membrane (Biorad),
blocked with 5% BSA for 1 h, RT, and immunoblotted
with anti-Apo-E antibody (1:1000), 1 h at RT. After
several washes with TBS-Tween-20 buffer (Tris-buff-
ered saline: 10 mM Tris-Cl, pH 7.5, 150 mM NaCl 1X
and 0.05% Tween 20) at RT, the membrane was
incubated with secondary antibodies for 1 h at RT.
Images were acquired using ChemiDoc Touch System
(Biorad). An image from the Ponceau stained mem-
brane was also taken as a loading control. Check
supplementary Table S5 for detailed information
regarding antibodies.
Statistical analysis
Protein-related statistics were obtained with Proteo-
meDiscoverer 2.2 (Quantitative analysis) and IPA
software, while functional-related statistical analysis
was performed with GraphPad Prism 7 software. For
functional assays, data were verified for normal dis-
tribution using Shapiro-Wilk normality test. The dif-
ference between the three groups (SE, SC, and either
shams or healthy mice as controls) was assessed with
either one-way ANOVA test and Tukey’s multiple
comparisons test for post hoc analysis, or Kruskal-
Wallis test and Dun’s test as post hoc analysis. Ex-
periments with two different categorical independent
variables (blood flow measurements within time)
were analyzed with a two-way ANOVA test com-
pleted with Tukey’s multiple comparisons test for
post hoc analyses. Data were presented as mean ±
SEM and differences were considered statistically sig-
nificant at p value < 0.05.
Results
Characterization of CACs
CACs were isolated and cultured as described [12].
By day 7, the ex vivo differentiated CACs were posi-
tive for the markers CD31, CD34, CD45, CD73,
CD105, CD146, CD309, CD14, and CD133 and nega-
tive for CD90 (supplementary figure S2). Additionally,
they were also double positive to FITC-UEA-1 and
Ac-LDL, in agreement with previous reports, confirm-
ing the identity of these cells [32].
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Progression of ischemic symptoms
In response to femoral ligation, a significant reduction
of blood flow (> 90%) was seen in all SE (ischemic,
CAC-treated mice) and SC (ischemic, no treatment)
mice right after surgery (p value < 0.001, Fig. 1b),
compared to basal ratios of shams (SH, without
ligation) and healthy controls (C), and these levels
remained until day 4, when animals were sacrificed.
On day 2, ischemic mice showed already symptoms of
inflammation and ischemia (reddish area and black
nails, reduced motility) and progressed to black nec-
rotic fingers in some cases (Fig. 1c). In this regard,
no significant differences were seen between SE and
SC untreated mice, indicating that the expected effect
of CACs was not detected in these initial phase, at
least externally.
CACs promote collateral vessel formation and
arteriogenesis
In response to surgery, a significant increase in the
number of vessels was seen on day 2 in SC and SE
mice (p value < 0.05), with a similar increase in both
groups, compared to the healthy group (C) (Fig. 1e).
By day 4, however, vascular density levels remained
higher only in the SE-treated mice, although not
significantly compared to controls, while decreased
significantly in SC mice compared to the values
seen for SC and also SE on day 2 (p value < 0.05).
In terms of diameter size (Fig. 1d, f), no changes were
seen on average on day 2 in the vessels of SC or SE
groups vs controls, although diameters were slightly
smaller in SC. On the other hand, the internal lumens
on day 4 were wider in CAC-treated mice compared to
day 2 (SE4 vs SE2, p value < 0.05) and, moreover,
compared to SC non-treated mice (SC4 vs SE4,
p value < 0.001, and SC2 vs SE4 p value< 0.01), while
the diameters for the SC group were smaller than day
2 (not significantly) and smaller than controls (SC4 vs
C, p value < 0.05).
Furthermore, classification based on the internal
lumen size (Fig. 1g) indicated that SC mice had
higher percentages of narrower vessels (< 10 μm) than
controls and SE mice, with a decrease of the lumen
area within time. On the other hand, SE mice showed
lower percentages of small vessels (< 10 μm) while
more vessels with bigger diameters (> 30 μm) com-
pared to C and SC groups. Additionally, the number
of wider vessels increased from day 2 to day 4 after
cell administration.
CACs migrate to the vessels of the ischemic area after
intramuscular administration
UEA1+ pre-labeled cells (directly administered, Fig. 2a)
but also UEA1 and hCD31+ cells (after tissue post-
staining, Fig. 2b, c) were found within the ischemic
tissues of SE-treated mice on day 2, most of them in
the vicinity of the blood vessels, demonstrating that
these cells migrate to the vasculature even after intra-
muscular injection. In fact, from the total of the
blood vessels detected on day 2, 5.51% of them had
incorporated UEA1+ CACs. We did not detect human
ECs by IHC on day 4.
The incorporation of human cells was also corrobo-
rated by in situ hybridization of human-specific Alu se-
quences (Fig. 2e), with hDNA detected on days 2 and 4.
Nevertheless, Alu-quantification showed lower amounts
of human material within the ischemic tissues on day 4
than on day 2, suggesting that the presence of infused
cells decreased within time.
Proteomic changes in response to ischemia and cell
administration
Derived from the proteomic analysis, 1938 proteins
were identified, which were related to several bio-
logical processes according to Gene Ontology data-
base (Fig. 3a), including among others, proteins
related to cell organization and biogenesis (719), cell
differentiation (216) and proliferation (66), cellular
component movement (131), cell communication (49)
and homeostasis (130), defense response (127), or cell
death (87).
The application of a label-free quantitative approach
allowed the identification of protein changes in response
to ischemia and/or CAC treatment (Fig. 3b). Thus, dif-
ferential protein expression was seen not only between
the ischemic non-treated mice (SC) and the sham, non-
ischemic mice on day 2 (343 proteins altered in SC2 vs
SH) and day 4 (234 proteins in SC4 vs SH), but also
between CAC-treated and SC non-treated mice, on day
2 (117 proteins altered in SE vs SC) and day 4 (187 pro-
teins in SE vs SC). Additionally, a PCA classification
based on differential protein expression clearly discrimi-
nated between controls and changes detected on days 2
and 4, suggesting that protein changes were also time-
dependent (Fig. 3c). Supplementary Tables ST1 and ST2
contain complete information about these quantification
data (abundance ratio and p value). As an example, to
validate proteomic data, upregulation seen for Apo-E in
both SC and SE mice compared to SH controls was con-
firmed by WB (Fig. 3f).
Interestingly, protein changes seen not only between
ischemic (SC) vs non-ischemic (SH) mice, but also be-
tween SE ischemic-treated mice (SE vs SC) were associ-
ated according to IPA databases, with atherosclerosis,
vascular lesion, artery occlusion, and PAOD, and also
with angiogenesis, vasculogenesis and vasculature devel-
opment, EC development, apoptosis, necrosis, cell move-
ment, and cell migration (Fig. 4). Tables 1 and 2 include
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Fig. 2 (See legend on next page.)
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the functional classification made for protein changes on
days 2 and 4 between SE and SC groups. Additionally,
supplementary tables ST3 and ST4 include information
regarding SC vs SH comparisons.
Detailed analysis indicated that most proteins were
upregulated (48% on day 2 and 55% on day 4) or
downregulated (28% and 25%) in both ischemic
groups, SE and SC, compared to SH (Fig. 5 and
Table 3). Among them, several proteins showed
higher over-expression in response to CACs than SC
(12 proteins in SE2/SC2, 59 SE4/SC4), while others
were downregulated in lower levels after cell treat-
ment (54 proteins, day 4). Additionally, some proteins
were altered only in the ischemic, non-treated mice
(27 proteins, SC2/SH and 3 proteins SC4/SH), while
other proteins were only altered after cell treatment
(21 proteins SE2/SH and 17 proteins SE4/SH). Finally,
some proteins were identified only in the SE and SC
but not in the SH group, probably as a result of the
ligation procedure (Table 3).
Overall, according to IPA analysis, protein changes
in response to CACs affected cell death, with reduced
apoptosis and necrosis from day 2 onwards, at the
same time, that promoted cell movement and extrava-
sation mainly from day 4 (Fig. 4). Such increase in
cell movement was mainly related to immune cells:
myeloid (granulocytes and monocytes) and lymphoid
cells.
In this regard, several proteins related to neutrophil
migration, adhesion, and extravasation were differentially
expressed in both SC and SE mice (Fig. 6a), suggesting
an intense mobilization of these cells into the injured tis-
sues. Indeed, IHC results confirmed the presence of a
high number of neutrophils in SC and SE in response to
ischemia (neutrophils were barely detected in shams, p
values< 0.05). Interestingly, on day 4, the number of
neutrophils increased even more in the SC mice, while
remained at similar levels in the SE mice, compared to
day 2 (Fig. 6c).
Discussion
Experimental and clinical studies have shown that
transplantation of BM-MNC- or PB-MNC-derived
EPCs contribute to revascularization after ischemic
events [26, 33, 34] improving angiogenesis and
vasculogenesis within the ischemic tissues [35, 36], al-
though the exact mechanisms remain still unclear.
Growing evidence demonstrates that the so-called
EPCs can be divided into two sub-types, early EPCs
(also known as CACs or MACs) and ECFCs, and they
both play a role in vascular homeostasis and endothe-
lial repair [15, 17]. In this regard, validation of the
regenerative potential of CACs and ECFCs is a pre-
requisite step to their application, alone or combined,
in clinical practice [15].
Herein, we focused on the role of CACs in CLI,
taking into account that these cells seem to promote
a significant recovery of blood flow after 7 days of
being administered in CLI animal models [37–41],
although they are barely detected after the second
week. Thus, we postulated that administration of
CACs must exert an effect at the molecular level
right on the first days after their mobilization into
the injured area, and such effect has to promote, in
the last term, the increased revascularization ob-
served, while the cells themselves are most probably
replaced by the host ones or simply do not proli-
ferate and die after having exerted their angiogenic
role.
In our study, a significant blood flow reduction was
seen after artery ligation (> 90%), and these levels
remained until day 4, when mice were sacrificed.
Additionally, ischemic symptoms such as limb inflam-
mation and necrotic nails were also seen, corroborat-
ing the ischemic process induced. As a result, an
increase in vascular density was detected on day 2 in
the ischemic mice (SE and SC), reflecting an expected
sprouting of angiogenic ECs in response to injury as
a result of reduced oxygen delivery into the damaged
tissues [42]. On day 4, however, only CAC-treated
mice maintained the vascularity enhanced after ische-
mia, showing as well a higher percentage of the ves-
sels with wider diameters than SC or the healthy
controls. All these data suggest that, despite not hav-
ing seen an initial recovery of blood flow, cells start
to exert their effect from the first moment they are
into the ischemic tissues, promoting an initial revas-
cularization by increasing the number of the vessels
and, moreover, enhancing the maturation of the
newly forming vasculature [43]. Moreover, the
(See figure on previous page.)
Fig. 2 Detection of human cells in CAC-treated mice by IHC and qPCR. Human cells were analyzed by IHC in the frontal muscles of SE left limbs
on days 2 and 4: a tissues infused with UEA1 pre-labeled cells, or tissues incubated with b UEA1 and anti-α-SMA antibody and c anti-hCD31, to
determine the location of CACs in the tissue. d Graphical representation of the number of human cells (number of cells/μm2) detected after IHC
labeling with anti-hCD31 and UEA1. e Quantification of human cells (number of cells/milligram of the tissue) by qPCR using human-specific Alu
sequences, with the SH group as the negative control. Data represented as mean ± SEM, n:4 per day/group. Significant differences were seen by
Kruskal-Wallis test and Dun’s test for multiple comparisons. *p value < 0.05
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presence of human CACs was confirmed by Alu-
quantification of hDNA and IHC assays, mainly on
day 2, and in fewer amounts on day 4, many of them
detected in the vessels even after intramuscular ad-
ministration. Taking into account that CACs are not
highly proliferative [21], such decrease should not be
surprising, although future research should confirm
the in vivo fate of these cells. Nevertheless, the
decrease in the number of administered cells within
time corroborated the assumption that, although
CACs mobilize to the injured area, they do not
participate themselves in the formation of the new
vessels [44], but they most probably contribute to re-
vascularization by triggering specific molecular
changes in the ischemic tissues, as stated before [45],
by inducing further mobilization of autologous cells,
promoting angiogenesis and/or arteriogenesis itself. In
this regard, the paracrine role assigned to CACs,
known to secrete angiogenic factors such as VEGF,
HGF, G-CSF, or GM-CSF [32], could help to explain
those changes.
Indeed, the further proteomic analysis identified
not only time-dependent protein variations but also
changes in response to ischemia (SC) and, more-
over, after CAC administration (SE). Thus, in re-
sponse to CACs, a tendency to restore proteins
downregulated by ischemia to basal levels was seen
in the CLI-treated mice on day 2 (SC2 vs SE2) for
proteins such as Desmoplakin (DSP) or
Microtubule-associated protein 4 (MAP 4). DSP par-
ticipates in microvascular tube formation, taking
part in de novo capillary formation and branching
during cardiovascular development [46] while MAP
4 promotes migration and proliferation of ECs
under hypoxia [47]. Additionally, changes detected
on day 4 in SE mice represented an increased re-
sponse against ischemia, for example, with proteins
related to oxidative stress and nitric oxide (NO)
bioavailability, a molecule with vasculo-protective
properties, and an important role in angiogenic re-
sponse after ischemia [33]. Among them, heme-
related proteins were found either upregulated
(hemoglobin, HB) or downregulated (myoglobin,
MB) in ischemic tissues, and even more after CAC
treatment (compared to controls). In the case of
HB, two different subunits (HB-alpha and HB-beta)
were identified upregulated in both SC and SE com-
pared to shams, and moreover, these subunits were
present in higher levels in the SE-treated mice on
day 4. Both subunits are required for the proper
functioning of HB as oxygen transport. Thus, an in-
crease of HB levels could help to increase oxygen
transport after the hypoxic situation induced by is-
chemia. Additionally, HB increase could promote
vascular tone through participating in the NO trans-
fer between ECs and vascular smooth muscle cells
[48]. On the other hand, decreased levels of MB, a
muscle-specific protein of oxidative metabolism,
could also induce NO bioavailability [49, 50].
Hemopexin (HPX), another protein related to oxida-
tive stress, was also upregulated after ischemia and
CAC treatment. HPX has a strong affinity for free
heme in plasma and can remove excessive free heme
that excess might be strongly cytotoxic for vascular
ECs [51].
Overall, according to the IPA software (which
allows determining the most likely pathways or
functions in which proteins of interest are involved,
based on biomedical literature and integrated
databases), the femoral ligation performed and,
moreover, CAC treatment, induced a cascade of
proteomic changes related not only to vasculogen-
esis, angiogenesis, cell migration, and tubule forma-
tion, but also to cell death, with clear correlation
with atherosclerosis as well as PAOD. Thus, a
significant increase of proteins related to cell
movement was seen on day 4, especially for immune
cells (myeloid cells, lymphoid cells, and phagocytes)
in SC and, moreover, in SE mice. More intensively,
CAC treatment seemed to affect neutrophil
mobilization, with several related proteins upregu-
lated on day 4, such as CD177, lipocalin-2 (LCN2)
or CD44. In response to injury, neutrophils are
usually the first cells infiltrating the damaged area,
mediating inflammation by releasing diverse meta-
bolites and pro-inflammatory cytokines against
(See figure on previous page.)
Fig. 3 Proteomic changes in response to ischemia and CAC treatment. a Functional classification of identified proteins based on Gene Ontology
Database (via ProteomeDiscoverer). b Volcano plots obtained after label free quantification, comparing protein levels in SE and SC, on days 2 and
4. Cut-off limits: p value < 0.05 and ratios for upregulated (> 1.5) or downregulated (< 0.6) proteins. Color legends: upregulated ( ) or
downregulated ( ) proteins, no significant changes ( ). c Principal component analysis (PCA) graph distributed groups (SE, SC, SH, and C) mainly
between controls and ischemic mice, but also per time (controls, day 2 and day 4). d Venn’s diagram showing the overlapping of proteins
differently expressed between SC and SH and also between SE/SC on both days analyzed. e Number of proteins upregulated (red) and
downregulated (green) by ischemia (SC/SH) and in response to CAC treatment (SE/SC) per day. f Validation by WB of proteomic results. As an
example, the results seen for ApoE are shown. Apo-E was upregulated in SC and SE mice compared to controls
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Fig. 4 (See legend on next page.)
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ischemia [52]. Thus, not surprisingly, a high
mobilization of neutrophils was detected already on
day 2 in both ischemic groups (SC and SE) but not
in shams. Interestingly, however, the number of
neutrophils continued increasing on day 4 only in
the ischemic, non-treated mice (SC) but not in the
CAC-treated ones. Although neutrophils are vital to
fight inflammatory agents, excessive accumulation
can also cause further injury by releasing high con-
centrations of cytolytic and cytotoxic molecules into
the damaged muscles and surrounding areas [53,
54]. Diverse studies have indicated that the modula-
tion of neutrophil functions constitute a complex
network based on the balance between stimulatory
and inhibitory pathways regulated by certain media-
tors (including cytokines, “classical” neuroendocrine
hormones, and bioactive lipids) [55]. According to
our results, the administration of CACs promoted
changes at a protein level that, on average, avoided
an excessive neutrophil infiltration into the ischemic
tissues. Thus, the upregulation of CD177 or LCN2
might induce neutrophil migration in CAC-treated
mice. CD177, a neutrophil-specific antigen, pro-
motes neutrophil migration in endothelium by
interacting with platelet endothelial cell adhesion
molecule-1 (PECAM-1) [56, 57]. In the same way,
LCN2, also known as neutrophil gelatinase-
associated lipocalin (NGAL), could significantly con-
tribute to neutrophil’s migration, since it constitutes
an important paracrine chemoattractant and a key
factor for neutrophil function in inflammation [58].
On the other hand, upregulation of proteins like
Alpha1-Antitrypsin, also referred to as α1-proteinase
inhibitor or SerpinA1, might help to explain the re-
duction of neutrophil infiltration seen on day 4 in
response to CACs. SerpinA1 is an acute-phase pro-
tein, the most abundant serine proteinase inhibitor
in human plasma, and, moreover, a potent regulator
of neutrophil activation via both protease inhibitory
and non-inhibitory functions [59]. Indeed, SerpinA1
can influence neutrophil chemotaxis preventing neu-
trophil activation independently to the proteinase
role [60]. More specifically, two isoforms of Ser-
pinA1, SerpinA1D and SerpinA1A, appeared upregu-
lated, in higher levels, in SE2 and SE4, respectively,
compared to SH and, moreover, compared to SC
mice (Table 3). Further research will help to eluci-
date the exact role of these protein isoforms as well
as the mechanisms through which CACs seem to
modulate neutrophil infiltration in order to avoid,
(See figure on previous page.)
Fig. 4 IPA functional networks for proteins differentially expressed in response to CAC treatment. a Hierarchical clustering of proteins differentially
expressed in CAC-treated (SE) vs ischemic non-treated (SC) mice. Major functions described for protein changes (p < 0.05) seen in CAC-treated
mice (SE) vs ischemic, non-treated mice (SC): b on day 2 and c day 4. Pathways were generated based on the information stored in the IPA
Software Knowledge base. Color legends: upregulated ( ) or downregulated ( ) proteins, no significant expression changes (●), predicted
activation (more or less confidence), and predicted inhibition (more or less confidence)
Table 1 Functional classification of differentially expressed proteins in CAC-treated mice (SE) vs ischemic non-treated mice (SC) on
day 2 after femoral ligation. Protein classification was made with the IPA software based on biomedical literature and integrated
databases. The table shows the most probable pathways or functions in which the proteins of interest are involved including the
main categories, the related functions or diseases, p value, molecules (protein names), and number of proteins per category. Legend:
upregulated, downregulated
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perhaps an excessive and unwanted inflammatory
response.
On the other hand, neutrophils not only partici-
pate in inflammation but they can also promote
vascularization by inducing angiogenesis via a pro-
angiogenic phenotype [61, 62]. In this regard, pro-
teins such as LCN2 have been found to induce
angiogenesis in several breast cancers [63] and up-
regulation of LCN2 has been shown to promote EC
tube formation and migration via iron and ROS-
related pathways in rat’s brain [64]. Moreover,
LCN2 is increased in atherosclerosis and upregu-
lated by hypoxia and MI [65], being actually con-
sidered a potential biomarker of early ischemic
acute kidney injury [66]. Additionally, the over-
expression of the glycoprotein CD44 in the ische-
mic tissues and, mainly after CAC administration,
could also represent a mechanism to promote
angiogenesis as well as protecting the tissue from
ischemia itself. CD44 is a cell surface protein
expressed on adult ECs but also in CACs and other
bone marrow-derived cells [67], where it works as a
receptor for hyaluronan, a molecule related with
blood vessel formation. Indeed, CD44/hyaluronan
interaction seems to be important to activate
relevant angiogenic signals [67, 68] including,
among others, the mobilization and further adhe-
sion of neutrophils to ECs, promoting the recruit-
ment of these cells into the damaged areas after the
ischemic process. CD44 could also participate in
the organization and stability of endothelial tubular
networks and EC proliferation [67, 68]. CD44 can
also bind to the proteoglycan Versican (VCAN),
which was upregulated in SC but even more in SE
mice, and this over-expression increased on day 4.
VCAN/CD44 interaction appears to be involved in
extracellular matrix remodeling, cell adhesion, pro-
liferation, migration, and survival, as well as angio-
genesis and maintenance of tissues during vascular
diseases [69, 70]. In addition, upregulation of
Leucine-rich alpha-2-glycoprotein 1 (LRG1) could
correlate with the capability of activated neutrophils
to release LRG1 from the granule compartment and
thus modulate the microenvironment in a paracrine
fashion [71]. Alternatively, LRG1 can also promote
cell proliferation, migration, and angiogenesis, by
interacting with the TGF-β accessory receptor
endoglin, thus modulating endothelial TGF-β sig-
naling pathways and collaborating in blood vessel
formation [72, 73].
Table 2 Functional classification of differentially expressed proteins in CAC-treated mice (SE) vs ischemic non-treated mice (SC) on
day 4 after femoral ligation. Protein classification was made with the IPA software based on biomedical literature and integrated
databases. The table shows the most probable pathways or functions in which the proteins of interest are involved including the
main categories, the related functions or diseases, p value, molecules (protein names), and number of proteins per category. Legend:
upregulated, downregulated
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Apart from neutrophils, monocytes and macro-
phages are required for the immune response and
also induce the growth and maturation of small
collateral arteries into conduit vessels (arteriogen-
esis), essential for restoration of blood flow to
ischemic organs [74]. In this regard, upregulation of
proteins such as MAP kinase-activated protein kin-
ase 2 (MAPKAPK2) by CACs represents an attempt
to promote arteriogenesis, since this protein plays a
key role in this process by inducing, during early
phases of hind limb ischemia, the production of
monocyte chemo-attractant protein-1 (MCP-1) by
ECs, and thus, monocyte migrates to the damaged
area [74]. MAPKAPK2 increase could therefore be
involved in monocyte/macrophage mobilization and
the increase of vessel diameters seen after CAC
administration.
Several members of the S100 family (S100A4,
S100A6, S100A9, and S100A11) were also found up-
regulated in ischemia and more intensively in
response to cell treatment. This family of calcium-
binding cytosolic proteins has a broad range of
Fig. 5 Differential protein expression patterns in CAC-treated mice and non-treated mice compared to shams. The circular chart represents the
percentages of proteins altered in both ischemic groups (SE and SC) compared to shams (SH), on days 2 and 4: upregulated (red ) or
downregulated proteins (green ) in SE and SC mice; proteins only modified in SC (dark blue ) or in SE mice (light blue ); proteins identified in
ischemic mice (SC, SE) but not in SH (purple ); others changes (yellow ). Additionally, the number of proteins differently expressed, with
different patterns within the groups described in the main chart is shown: upregulated (a) or downregulated (b) proteins in SE and SC vs SH,
proteins only modified in SC (c) or in CAC-treated mice (d)
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intracellular and extracellular functions participating
in proliferation, differentiation, apoptosis, Ca2+
homeostasis, energy metabolism, inflammation,
leukocyte adhesion and migration, and tissue repair
[75, 76]. Among others, the release of S100A8/A9
has been suggested to facilitate monocyte and
neutrophil transmigration. These proteins are also
considered as damage-associated molecular pattern
(DAMP) molecules, since they appear to be released
by damaged or stressed cells becoming danger sig-
nals that derive in the activation of immune and
ECs by binding to the pattern recognition receptors
such as TLRs and RAGE [76]. At relatively high
concentrations, the S100A8/A9 complex inhibits the
growth of a variety of normal cell types (macro-
phages, bone marrow cells, lymphocytes, fibroblasts)
[75]. As DAMP molecules, S100 proteins also par-
ticipate as either pro- or anti-apoptotic proteins de-
pending on the cell type as well as the pathological
process they are involved in. For example, down-
regulation of S100A6 has been related with an in-
creased cell cycle arrest in the G2/M phase of cell
cycle and downregulation of genes with effects on
cell cycle progression [75, 77].
Not only S100A6 but also other altered levels of
pro- and anti-apoptotic proteins could be found in
the first days in SC and SE mice, with downregulation
(more significant in SE) of pro-apoptotic proteins like
mitochondrial carrier homolog 1 (MTCH1), B cell
lymphoma (BCL)-2 like protein 13 (BCL2L13) [78] or
anti-apoptotic ones like BCL2-associated Athanogene
3 (BAG3), which also promotes autophagy by associ-
ating with BCL-2 or Beclin 1 [79]. Apoptosis is trig-
gered in ischemic tissues in order to remove damaged
or unhealthy cells, accompanied by the repair of lost
tissues via the active proliferation of the intact cell
components. Autophagy, on the other hand, is an
adaptive response to environmental stresses including
nutrient starvation due to tissue destruction or blood
shortage, and it seems to be also required for the
development of vascular ECs [80]. Downregulation of
BAG3 could represent an increase in apoptosis but
reduced autophagy [79, 81], mainly in the CAC-
treated mice, although further studies should confirm
such hypothesis. Overall, protein changes (upregula-
tion and downregulation) taking place in ischemic
non-treated mice indicated an upregulation of apop-
tosis and necrosis (according to the IPA functional
Table 3 Classification of differentially expressed proteins in CAC-treated mice (SE) and non-treated mice (SC) vs shams (SH) on days
2 and 4 after femoral ligation. Protein classification was made based on the effect of CAC treatment over protein expression,
compared to ischemic as well as basal levels (promoting higher changes or restoring proteins to basal levels). The table shows
protein variations in SE and SC vs SH detected on day 2 and 4, the names of the proteins altered in each case as well as the most
probably functions in which the proteins are involved, according to IPA-integrated databases. Legend: upregulated,
downregulated
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analysis), while cell treatment seemed to modulate
such phenomena. Similarly, transplantation of human
peripheral blood-derived CD31+ cells significantly re-
duced endothelial cell apoptosis compared to control
groups suggesting protective effects on existing vessels
[82]. Angiogenic factors not only induce angiogenesis
but also act as a survival factor and can potentially
block endothelial cell apoptosis and protect micro-
vascular endothelium from programmed cell death
[83, 84]. The imbalance seen between apoptosis/ne-
crosis and cell proliferation could help to explain why
in the absence of such angiogenic promoters, ECs die
without being able to proliferate [84] while CAC
treatment induced in SE mice has a stable cell
sprouting and/or neovascularization as well as matur-
ation of an appropriate vasculature network, probably
modulating apoptosis to allow revascularization and
blood flow recovery.
Overall, we have shown here, for the first time to
our knowledge, a complete map of protein/molecular
changes taking place right after inducing ischemia in
a CLI model and, moreover, in response to CAC
treatment. A functional classification has allowed to
provide an overview of the proteins identified herein.
Many of them have been previously correlated with
response to ischemia (MAP 4, HPX, S100A proteins)
as well as with angiogenic- and revascularization-
related processes (LCN2, LRG1, CD44, MAPKAPK2).
Other proteins will require further evaluation to
confirm whether they promote indeed the effects
described. Our findings bring the opportunity for
future research to explore the precise role of the
differential proteins identified in response to CAC
administration.
Conclusions
Our data confirmed that CACs migrate to the vascu-
lature of the injured area, contributing to the forma-
tion of the new vessels, although they are most
probably replaced by autologous ECs or simply dis-
appear; due to the short time, they can be traced
within the ischemic tissues, supporting the paracrine
role assigned to these cells. Furthermore, the protein
changes identified indicate that, from the first
Fig. 6 CAC administration modulates the recruitment of neutrophils to the ischemic tissues. a Functional analysis of the proteomic changes
detected in response to CACs (SE vs SC, p < 0.05), indicated that these changes were involved in neutrophil recruitment (migration, adhesion, and
transmigration) and neutrophil participation of the immune response. Pathways were obtained with the IPA software. b Detection of mouse
neutrophils by IHC in the left hind limb frontal muscle labeling with Ly-6G antibody on days 2 and 4 in treated, non-treated, and sham mice. c
Determination of neutrophils number (neutrophils/mm2) in treated, non-treated, and sham mice. Data were presented as mean ± SEM. Significant
differences were found between SH (with no neutrophils) and the other groups: *p value < 0.05, ***p value < 0.001, by one-way ANOVA and
Tukey post hoc test
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moment, CACs seem to trigger a set of mechanisms
ranging from the recruitment of immune and other
cells (participating in the inflammatory response but
also contributing to vascular remodeling), vessel for-
mation, and arteriogenesis (as it can be seen in the
first days already), as well as cell apoptosis, probably
to modulate an appropriate development of the vascu-
lar network.
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